TY - JOUR
T1 - 1a,25-Dihydroxyvitamin D3 Encapsulated in Nanoparticles Prevents Venous Neointimal Hyperplasia and Stenosis in Porcine Arteriovenous Fistulas
AU - Singh, Avishek K.
AU - Cai, Chuanqi
AU - Kilari, Sreenivasulu
AU - Zhao, Chenglei
AU - Simeon, Michael L.
AU - Takahashi, Edwin
AU - Edelman, Elazer R.
AU - Kong, Hyunjoon
AU - Macedo, Thanila
AU - Singh, Ravinder J.
AU - Urban, Matthew W.
AU - Kumar, Rajiv
AU - Misra, Sanjay
N1 - Funding Information:
A US patent (WO2016011397A1) has been issued for the use of 1,25 NP. E.R. Edelman reports consultancy agreements with Abbvie, Abiomed, Alu-cent, Autus, Biodevek, CBSET, Edwards Life Sciences, Panther, Peregrine, and Tekla; reports having an ownership interest in Autus, BioDevek, and Panther; reports receiving research funding from Abiomed and Edwards Life Sciences; reports having patents and inventions with the Massachusetts Institute of Technology; and reports being a scientific advisor to or member of American Association for the Advancement of Science and the Food and Drug Administration. H. Kong reports being a scientific advisor to or membership of Biomaterials Journal, Biofabrication Journal, and Biomaterials Research. M. Urban reports consultancy agreements with Michigan State University; reports receiving research funding from Computerized Imaging Reference Systems, Incorporated and the National Institutes of Health (NIH) grants R01DK092255, R01HL145268; and reports having patents and inventions with General Electric Healthcare. R. Kumar reports consultancy agreements with Orfan; reports having an ownership interest in Orfan; reports receiving research funding from the Andersen Foundation and NIH; reports receiving honoraria from Bridgebio Pharma and Orfan; and reports being a scientific advisor to or membership of Bridgebio Pharma. S. Misra reports receiving research funding from NIH grants.
Funding Information:
This work has been funded by NIH grants HL098967 and DK107870 (to S. Misra). E.R. Edelman was funded in part by NIH grant R01 49039.
Publisher Copyright:
Copyright © 2021 by the American Society of Nephrology.
PY - 2021/4
Y1 - 2021/4
N2 - Background Few therapies prevent venous neointimal hyperplasia (VNH) and venous stenosis (VS) formation in arteriovenous fistulas (AVF). Expression of the immediate early response gene X-1 (Iex-1), also known as Ier3, is associated with VNH and stenosis in murine AVFs. The study aimed to determine if local release of Ier3 long-acting inhibitor 1a,25(OH)2D3 from poly(lactic-co-glycolic acid) (PLGA) nanoparticles embedded in a thermosensitive Pluronic F127 hydrogel (1,25 NP) could affect VNH/VS formation in a large animal model. Methods Immediately after AVF creation in a porcine model of renal failure, 1,25 NP or vehicle control was injected into the adventitia space of AVF outflow veins. Scanning electron microscopy and dynamic light scattering characterized drug and control nanoparticles. Animals were sacrificed 3 and 28 days later for gene expression, immunohistologic, magnetic resonance imaging and angiography, and ultrasound analyses. Whole transcriptome RNA sequencing with differential gene expression analysis was performed on outflow veins of AVF. Results Encapsulation of 1a,25(OH)2D3 in PLGA nanoparticles formed nanoparticles of uniform size that were similar to nanoparticles without 1a,25(OH)2D3. The 1,25 NP–treated AVFs exhibited lower VNH/VS, Ier3 gene expression, and IER-3, MCP-1, CD68, HIF-1a, and VEGF-A immunostaining, fibrosis, and proliferation. Blood flow and lumen area increased significantly, whereas peak systolic velocity and wall shear stress decreased. Treatment increased Young’s modulus and correlated with histologic assessment of fibrosis and with no evidence of vascular calcification. RNA sequencing analysis showed changes in the expression of genes associated with inflammatory, TGFb1, and apoptotic pathways. Conclusions Local release of 1,25 NP improves AVF flow and hemodynamics, and reduces stenosis in association with reduction in inflammation, apoptosis, and fibrosis in a porcine model of arteriovenous fistula.
AB - Background Few therapies prevent venous neointimal hyperplasia (VNH) and venous stenosis (VS) formation in arteriovenous fistulas (AVF). Expression of the immediate early response gene X-1 (Iex-1), also known as Ier3, is associated with VNH and stenosis in murine AVFs. The study aimed to determine if local release of Ier3 long-acting inhibitor 1a,25(OH)2D3 from poly(lactic-co-glycolic acid) (PLGA) nanoparticles embedded in a thermosensitive Pluronic F127 hydrogel (1,25 NP) could affect VNH/VS formation in a large animal model. Methods Immediately after AVF creation in a porcine model of renal failure, 1,25 NP or vehicle control was injected into the adventitia space of AVF outflow veins. Scanning electron microscopy and dynamic light scattering characterized drug and control nanoparticles. Animals were sacrificed 3 and 28 days later for gene expression, immunohistologic, magnetic resonance imaging and angiography, and ultrasound analyses. Whole transcriptome RNA sequencing with differential gene expression analysis was performed on outflow veins of AVF. Results Encapsulation of 1a,25(OH)2D3 in PLGA nanoparticles formed nanoparticles of uniform size that were similar to nanoparticles without 1a,25(OH)2D3. The 1,25 NP–treated AVFs exhibited lower VNH/VS, Ier3 gene expression, and IER-3, MCP-1, CD68, HIF-1a, and VEGF-A immunostaining, fibrosis, and proliferation. Blood flow and lumen area increased significantly, whereas peak systolic velocity and wall shear stress decreased. Treatment increased Young’s modulus and correlated with histologic assessment of fibrosis and with no evidence of vascular calcification. RNA sequencing analysis showed changes in the expression of genes associated with inflammatory, TGFb1, and apoptotic pathways. Conclusions Local release of 1,25 NP improves AVF flow and hemodynamics, and reduces stenosis in association with reduction in inflammation, apoptosis, and fibrosis in a porcine model of arteriovenous fistula.
UR - http://www.scopus.com/inward/record.url?scp=85104768540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104768540&partnerID=8YFLogxK
U2 - 10.1681/ASN.2020060832
DO - 10.1681/ASN.2020060832
M3 - Article
C2 - 33627344
AN - SCOPUS:85104768540
SN - 1046-6673
VL - 32
SP - 866
EP - 885
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
IS - 4
ER -